Lin Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lin Lu has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Fei Hou
Department of Nuclear Medicine, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan, Kunming, China
36 shared publications - Haolin Cai
Department of Nuclear Medicine, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan, Kunming, China
36 shared publications - Hongbo Zhao
Department of Laboratory Animal Science, Kunming Medical University, Kunming, China
36 shared publications - Ting Chen
Department of Nuclear Medicine, Fuwai Yunnan Cardiovascular Hospital, Chinese Academy of Medical Sciences (Affiliated Cardiovascular Hospital of Kunming Medical University), Kunming, 528 Shahe North Road, Wuhua District, China.
36 shared publications - Xiaoqi Peng
Department of Nuclear Medicine, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan, Kunming, China
36 shared publications - Yinghui Wang
Department of Nuclear Medicine, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan, Kunming, China
36 shared publications
Latest Publications
- 1 April 2026
- Published by Wiley in Molecular Oral Microbiology
- Vol. 41 (4) , 216-226
Ginsenoside Compound K Plays an Anti‐Inflammatory Role in Gingival Epithelial Cells Stimulated With Porphyromonas gingivalis by Regulating Pyruvate Kinase M2
Background: Globally prevalent periodontitis, an inflammatory disease, may be associated with glucose metabolism disorders. Pyruvate kinase M2 (PKM2), the key enzyme of glycolysis, is potentially implicated in periodontitis pathogenesis, although its precise role is unclear. Ginsenoside compound K (CK) has strong anti‐inflammatory effects. Prior studies indicate that CK down‐regulates PKM2 expression, yet it remains unclear whether CK can regulate PKM2 to modulate the inflammatory response. Furthermore, CK's role in periodontitis lacks pharmacological investigation. Methods: A periodontitis cell model was established by stimulating human gingival epithelial cells (HGECs) with Porphyromonas gingivalis ( Pg ), and subsequently intervened with CK. Western blotting assessed the expressions of PKM2, phospho‐PKM2 (Tyr105), nuclear factor kappa‐B P65 (NF‐κB P65), and phosphorylated NF‐κB p65 (Ser536). Enzyme‐linked immunosorbent assay measured interleukin 1β (IL‐1β) and tumor necrosis factor‐α (TNF‐α) levels in culture supernatants. Results: Pg stimulation induced NF‐κB p65 (Ser536) activation and the secretion of IL‐1β and TNF‐α in HGECs and promoted PKM2 (Tyr105) phosphorylation. PKM2 was found to be the upstream regulator of NF‐κB p65, and NF‐κB p65 activated PKM2 through positive feedback to promote IL‐1β and TNF‐α production, forming a feedback regulatory loop. CK inhibited Pg ‐induced inflammation and NF‐κB p65 (Ser536) and PKM2 (Tyr105) phosphorylation in HGECs. Furthermore, PKM2 overexpression significantly reversed CK's anti‐inflammatory effects. Conclusions: The PKM2/NF‐κB p65 pathway is involved in regulating the expression of inflammatory cytokines in Pg ‐stimulated HGECs and serves as a crucial inflammatory regulatory pathway in the Pg ‐stimulated HGECs model. CK exhibits anti‐inflammatory activity by inhibiting the PKM2‐mediated NF‐κB signaling pathway and has potential as PKM2 modulator for treating periodontitis and other inflammatory diseases.
- 1 April 2026
- Published by Wiley in Molecular Oral Microbiology
- Vol. 41 (4) , 216-226
Ginsenoside Compound K Plays an Anti‐Inflammatory Role in Gingival Epithelial Cells Stimulated With Porphyromonas gingivalis by Regulating Pyruvate Kinase M2
Background: Globally prevalent periodontitis, an inflammatory disease, may be associated with glucose metabolism disorders. Pyruvate kinase M2 (PKM2), the key enzyme of glycolysis, is potentially implicated in periodontitis pathogenesis, although its precise role is unclear. Ginsenoside compound K (CK) has strong anti‐inflammatory effects. Prior studies indicate that CK down‐regulates PKM2 expression, yet it remains unclear whether CK can regulate PKM2 to modulate the inflammatory response. Furthermore, CK's role in periodontitis lacks pharmacological investigation. Methods: A periodontitis cell model was established by stimulating human gingival epithelial cells (HGECs) with Porphyromonas gingivalis ( Pg ), and subsequently intervened with CK. Western blotting assessed the expressions of PKM2, phospho‐PKM2 (Tyr105), nuclear factor kappa‐B P65 (NF‐κB P65), and phosphorylated NF‐κB p65 (Ser536). Enzyme‐linked immunosorbent assay measured interleukin 1β (IL‐1β) and tumor necrosis factor‐α (TNF‐α) levels in culture supernatants. Results: Pg stimulation induced NF‐κB p65 (Ser536) activation and the secretion of IL‐1β and TNF‐α in HGECs and promoted PKM2 (Tyr105) phosphorylation. PKM2 was found to be the upstream regulator of NF‐κB p65, and NF‐κB p65 activated PKM2 through positive feedback to promote IL‐1β and TNF‐α production, forming a feedback regulatory loop. CK inhibited Pg ‐induced inflammation and NF‐κB p65 (Ser536) and PKM2 (Tyr105) phosphorylation in HGECs. Furthermore, PKM2 overexpression significantly reversed CK's anti‐inflammatory effects. Conclusions: The PKM2/NF‐κB p65 pathway is involved in regulating the expression of inflammatory cytokines in Pg ‐stimulated HGECs and serves as a crucial inflammatory regulatory pathway in the Pg ‐stimulated HGECs model. CK exhibits anti‐inflammatory activity by inhibiting the PKM2‐mediated NF‐κB signaling pathway and has potential as PKM2 modulator for treating periodontitis and other inflammatory diseases.
- Top Cited PapersOpen Access
- 31 October 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 77, 102913
Development and validation of an interpretable machine learning model for predicting the risk of distant metastasis in papillary thyroid cancer: a multicenter study
- 31 October 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 77, 102913
Top Cited PapersOpen AccessDevelopment and validation of an interpretable machine learning model for predicting the risk of distant metastasis in papillary thyroid cancer: a multicenter study
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Figure S5. Protein expression categorized into 4 levels.
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Figure S5. Protein expression categorized into 4 levels.
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Table S2. Relevant clinical information of 44 LMDTC and 25 NMDTC patients used for 4D Label-free proteomic analysis, PRM, and IHC dual validation
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Table S2. Relevant clinical information of 44 LMDTC and 25 NMDTC patients used for 4D Label-free proteomic analysis, PRM, and IHC dual validation
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Table S6. Proteins with degree>40 in the PPI network
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Table S6. Proteins with degree>40 in the PPI network
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Figure S4. WGCNA analysis of the proteomics data.
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Figure S4. WGCNA analysis of the proteomics data.
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Material S1 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
KEGG Analysis Table of Differential Proteins
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Material S1 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
KEGG Analysis Table of Differential Proteins
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Table S3. Conditions for setting up PRM quantitative peptide segments
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Table S3. Conditions for setting up PRM quantitative peptide segments
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Figure S2. Principal component analysis of patients in LMDTC (M) group and NMDTC (NM) group.
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Figure S2. Principal component analysis of patients in LMDTC (M) group and NMDTC (NM) group.
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Figure S1. Statistical chart of protein identification results.
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Biomarker Identification and Risk Prediction Model Development for Differentiated Thyroid Carcinoma Lung Metastasis Based on Primary Lesion Proteomics
Figure S1. Statistical chart of protein identification results.